Announcement on the Approval for MAA of the Allogeneic iPS Cell-Derived Dopaminergic Neural Progenitor Cell Product “AMCHEPRY” in Japan3/6TDnetPDF(200KB)
Regarding the Scheduled Review in Japan of the Allogeneic iPS Cell-Derived dopaminergic neural progenitor cells (AMCHEPRY)2/13TDnetPDF(138KB)
Supplementary Financial Data (IFRS) for the Third Quarter of the Year Ending March 31, 20261/30TDnetPDF(261KB)
Summary of Consolidated Financial Results for the Nine Months Ended December 31, 2025 [IFRS]1/30TDnetPDF(446KB)
米国血液学会(ASH)2025における開発中の抗がん剤enzomenib(DSP-5336)およびnuvisertib(TP-3654)に関する最新の臨床データ発表のお知らせ12/9TDnetPDF(246KB)
Supplementary Financial Data (IFRS) for the Second Quarter of the Year Ending March 31, 202610/31TDnetPDF(270KB)
Summary of Consolidated Financial Results for the Second Quarter (First Half) of the Year Ending March 31, 2026 [IFRS]10/31TDnetPDF(464KB)
(Progress of Disclosure Matters) Confirmation of Gain on Sales of Shares of Subsidiaries in connection with the Company Split of Asian Business10/31TDnetPDF(149KB)